Idiopathic Pulmonary Fibrosis Job Exposures Study (IPFJES)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03211507 |
Recruitment Status
:
Recruiting
First Posted
: July 7, 2017
Last Update Posted
: July 7, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
IPF Idiopathic Pulmonary Fibrosis | Other: Computer-assisted telephone interview Genetic: Genetic analysis |
Study Type : | Observational |
Estimated Enrollment : | 920 participants |
Observational Model: | Case-Control |
Time Perspective: | Prospective |
Official Title: | Idiopathic Pulmonary Fibrosis Job Exposures Study |
Actual Study Start Date : | May 1, 2017 |
Estimated Primary Completion Date : | October 5, 2019 |
Estimated Study Completion Date : | October 5, 2020 |

Group/Cohort | Intervention/treatment |
---|---|
Case
Males with an incident diagnosis of IPF
|
Other: Computer-assisted telephone interview
Occupational history
Genetic: Genetic analysis
To include analysis of known susceptibility markers
|
Controls
Males with an incident hospital outpatient attendance who do not have IPF
|
Other: Computer-assisted telephone interview
Occupational history
Genetic: Genetic analysis
To include analysis of known susceptibility markers
|
- Association between asbestos exposure and IPF [ Time Frame: 2 years ]estimated using logistic regression for any vs no asbestos exposure and adjusting for age and smoking status
- Dose-response relationship between asbestos exposure and IPF [ Time Frame: 2 years ]estimated using logistic regression for categories of cumulative exposure and adjusting for age and smoking status
- Gene-environment interaction (for MUC5B rs35705950 and asbestos exposure) odds ratio. [ Time Frame: 2 years ]MUC5B rs35705950 and asbestos exposure odds ratio.
Biospecimen Retention: Samples With DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Senior |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
For cases
Inclusion Criteria:
- New diagnosis of IPF between February 2017 and October 2019
Exclusion Criteria:
- Unable to give informed consent
- Ever worked outside of the UK
For controls
Inclusion Criteria:
- New outpatient department attendee between February 2017 and October 2019
Exclusion Criteria:
- Unable to give informed consent
- Ever worked outside of the UK (does not include work outside the UK by members of the armed forces or merchant navy)
- Diagnosis of IPF

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03211507
Contact: Carl Reynolds | +44 (0)207 352 8121 ext 3364 | carl.reynolds@imperial.ac.uk | |
Contact: Paul Cullinan | p.cullinan@imperial.ac.uk |
United Kingdom | |
Imperial Healthcare NHS Trust | Recruiting |
London, United Kingdom | |
Contact: Carl Reynolds, MBBS |
Study Director: | Carl Reynolds | Imperial College London |
Additional Information:
Responsible Party: | Imperial College London |
ClinicalTrials.gov Identifier: | NCT03211507 History of Changes |
Other Study ID Numbers: |
16SM3627 |
First Posted: | July 7, 2017 Key Record Dates |
Last Update Posted: | July 7, 2017 |
Last Verified: | July 2017 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No | |
Studies a U.S. FDA-regulated Device Product: | No |
Additional relevant MeSH terms:
Fibrosis Pulmonary Fibrosis Idiopathic Pulmonary Fibrosis Idiopathic Interstitial Pneumonias |
Pathologic Processes Lung Diseases Respiratory Tract Diseases Lung Diseases, Interstitial |